Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

N Voloshyna, E Havrdová, M Hutchinson, T Nehrych, X You, S Belachew, C Hotermans, D Paes, N Voloshyna, E Havrdová, M Hutchinson, T Nehrych, X You, S Belachew, C Hotermans, D Paes

Abstract

Background and purpose: Impaired ambulation is a prominent disabling symptom of multiple sclerosis and can lead to reduced quality of life. Whether natalizumab, a monoclonal antibody shown to reduce disease activity in relapsing-remitting multiple sclerosis, could impact ambulation performance was examined.

Methods: A prospective open-label study, TIMER, was conducted in natalizumab-naive patients (n = 215). The timed 25-foot walk (T25FW) and timed 100-m walk (T100MW) were assessed at baseline and at weeks 24 and 48 of natalizumab therapy, together with Expanded Disability Status Scale scores. The effects of natalizumab on T25FW performance were also examined in a retrospective analysis of natalizumab-treated patients (n = 627) and placebo control patients (n = 315) from the AFFIRM study.

Results: In TIMER, a significant increase from baseline in T25FW speed was seen at week 24 (P = 0.0074) and in T100MW speed at weeks 24 and 48 (both P < 0.001). A greater proportion of patients showed clinically meaningful increases (≥20%) in walking speed on the T100MW (25%) than on the T25FW (13%) at week 48 (P = 0.032). In AFFIRM, natalizumab increased the proportion of patients with ≥20% confirmed improvement in T25FW speed at year 2 by 78% versus placebo (P = 0.0133).

Conclusions: Natalizumab increased walking speed in patients with relapsing-remitting multiple sclerosis. The T100MW may be more sensitive to changes in ambulation capacity than the T25FW, and both tests appear to detect clinically meaningful improvements in ambulatory function.

Keywords: Expanded Disability Status Scale; ambulation; natalizumab; quality of life; relapsing−remitting multiple sclerosis; timed 100-meter walk; timed 25-foot walk; walking.

© 2014 Biogen Idec. European Journal Of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Figures

Figure 1
Figure 1
Changes in walking performance over time in TIMER.
Figure 2
Figure 2
Clinically meaningful improvements in ambulation in TIMER.
Figure 3
Figure 3
Improvements in ambulation in patients stratified by (a) baseline EDSS score and (b) baseline T25FW performance in TIMER.
Figure 4
Figure 4
Ambulation status in patients with improved or stable EDSS scores in TIMER. *P = 0.0025.

References

    1. van Asch P. Impact of mobility impairment in multiple sclerosis 2 − patients' perspectives. Eur Neurol Rev. 2011;6:115–120.
    1. Heesen C, Böhm J, Reich C, Kasper J, Goebel M, Gold SM. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler. 2008;14:988–991.
    1. Pike J, Jones E, Rajagopalan K, Piercy J, Anderson P. Social and economic burden of walking and mobility problems in multiple sclerosis. BMC Neurol. 2012;12:94.
    1. LaRocca NG. Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. Patient. 2011;4:189–201.
    1. Kaufman M, Moyer D, Norton J. The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite. Mult Scler. 2000;6:286–290.
    1. Kieseier BC, Pozzilli C. Assessing walking disability in multiple sclerosis. Mult Scler. 2012;18:914–924.
    1. Phan-Ba R, Pace A, Calay P, et al. Comparison of the timed 25-foot and the 100-meter walk as performance measures in multiple sclerosis. Neurorehabil Neural Repair. 2011;25:672–679.
    1. Rudick RA, Sandrock A. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother. 2004;4:571–580.
    1. Polman CH, O'Connor PW, Havrdová E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.
    1. Phillips JT, Giovannoni G, Lublin FD, et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler. 2011;17:970–979.
    1. Havrdová E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing−Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254–260.
    1. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol. 2005;58:840–846.
    1. Hobart J, Blight AR, Goodman A, Lynn F, Putzki N. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology. 2013;80:1509–1517.
    1. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122:871–882.
    1. Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007;62:335–346.
    1. Goldman MD, Motl RW, Scagnelli J, et al. Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world. Neurology. 2013;81:1856–1863.
    1. Cadavid D, Jurgensen S, Lee S. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing−remitting multiple sclerosis. PLoS One. 2013;8:e53297.
    1. Belachew S, Phan-Ba R, Bartholome E, et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing−remitting multiple sclerosis. Eur J Neurol. 2011;18:240–245.
    1. Svenningsson A, Falk E, Celius EG, et al. Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting. PLoS One. 2013;8:e58643.
    1. Cadavid D, Tang Y, O'Neill G. Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis. Rev Neurol. 2010;51:321–329. [Article in Spanish]
    1. Bosma L, Kragt JJ, Polman CH, Uitdehaag BM. Walking speed, rather than Expanded Disability Status Scale, relates to long-term patient-reported impact in progressive MS. Mult Scler. 2013;19:326–333.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する